Welcome to our dedicated page for Ionq SEC filings (Ticker: IONQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IonQ, Inc. filings document a public quantum technology company with common stock, warrants and recurring capital-structure disclosures. Its 8-K reports include operating and financial results, material-event updates, registration rights agreements, unregistered equity issuances, resale prospectus supplements and acquisition-related share issuances, including the completed Skyloom Global acquisition.
IonQ proxy materials cover shareholder voting matters, board governance, executive compensation and pay-versus-performance disclosures. The company’s filing record also reflects material agreements, warrant and common-stock terms, financial reporting furnished with earnings releases, and governance matters connected to its quantum computing, networking, sensing, security and space-based data businesses.
IonQ Form 3 summary: Raymond John W filed an initial Form 3 reporting his relationship to IonQ as a Director and that no securities are beneficially owned as of the 09/25/2025 event date. The filing includes an Exhibit 24 Power of Attorney and is signed by an attorney-in-fact, Kevin Caimi, dated 09/29/2025. The report indicates it was filed by one reporting person and provides the reporting person’s address at IonQ’s College Park, MD location.
IonQ, Inc. reported that its Board of Directors appointed John W. Raymond as a new Class I director, effective September 25, 2025. His term will run until the company’s 2028 annual meeting of stockholders. The Board acted on the recommendation of its Nominating and Corporate Governance Committee.
The company states there are no special arrangements, family relationships, or related-party transactions involving General Raymond that require disclosure. As a non-employee director, he is eligible for the standard compensation program, which currently includes an annual cash retainer of $147,500, paid quarterly, and an initial restricted stock unit award with a grant date value equal to a pro-rated portion of the $220,000 annual RSU grant. IonQ also entered into its standard indemnification agreement with him, providing protection to the fullest extent permitted under Delaware law. As General Raymond joins the Board, Bill Scannell is expected to resign as a director and assume the role of Senior Commercial Advisor.
Insider reported RSU awards and resulting beneficial ownership in IonQ, Inc. (IONQ). Robert T. Cardillo received two restricted stock unit awards on 09/10/2025: 45,600 RSUs that vest over four years (25% on 09/10/2026, then quarterly 1/16 on each Dec 10, Mar 10, Jun 10, Sep 10) and 31,920 RSUs that vest in full on 09/10/2027, both conditioned on continued service. Both awards were reported with a transaction price of $0. After the first award the reporting person beneficially owned 83,036 shares, and after the second award 114,956 shares. The filing was signed by an attorney-in-fact on 09/25/2025.
IonQ amended a prior 8-K to correct a typographical error and to confirm transaction terms. The amendment states the company delivered 25,372,150 shares of common stock plus $10,000,000 cash as the aggregate consideration at closing for the acquisition of Oxford Ionics Limited. The amendment corrects an earlier, incorrect share amount of 26,622,077. It also discloses a proposed issuance of 6,294,058 shares in connection with the Vector Atomic transaction, expected to close in the fourth quarter of 2025 and subject to customary conditions. The filing references a registration rights agreement and related press releases and confirms reliance on private offering exemptions for the share issuances.
IonQ amended a prior 8-K to correct a typographical error and to confirm transaction terms. The amendment states the company delivered 25,372,150 shares of common stock plus $10,000,000 cash as the aggregate consideration at closing for the acquisition of Oxford Ionics Limited. The amendment corrects an earlier, incorrect share amount of 26,622,077. It also discloses a proposed issuance of 6,294,058 shares in connection with the Vector Atomic transaction, expected to close in the fourth quarter of 2025 and subject to customary conditions. The filing references a registration rights agreement and related press releases and confirms reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ announced a material acquisition and a separate pending equity transaction. The company completed the acquisition of Oxford Ionics by issuing 26,622,077 shares of common stock plus $10,000,000 in cash as consideration. IonQ also entered into an agreement to issue 6,294,058 shares to acquire Vector Atomic, with that transaction expected to close in the fourth quarter of 2025 subject to customary closing conditions. The filings referenced a Registration Rights Agreement related to Oxford Science Enterprises plc and press releases announcing the Oxford Ionics closing and the Vector Atomic agreement. The disclosure indicates reliance on private offering exemptions for the share issuances.
IonQ director Robert T. Cardillo exercised and sold company stock under a Rule 10b5-1 plan. On 09/12/2025 the reporting person exercised a stock option with an $11.24 exercise price to acquire 8,773 shares and immediately sold 8,773 shares at a weighted-average price of $50.5177, with individual sale prices ranging from $47.38 to $55.65.
Following these transactions the reporting person beneficially owned 37,436 shares. The Form 4 states the trades were executed pursuant to a 10b5-1 trading plan adopted March 12, 2025 and amended June 13, 2025, and discloses vesting terms for the option: one-third vested on February 26, 2025 with annual vesting thereafter.
IonQ director Robert T. Cardillo exercised and sold company stock under a Rule 10b5-1 plan. On 09/12/2025 the reporting person exercised a stock option with an $11.24 exercise price to acquire 8,773 shares and immediately sold 8,773 shares at a weighted-average price of $50.5177, with individual sale prices ranging from $47.38 to $55.65.
Following these transactions the reporting person beneficially owned 37,436 shares. The Form 4 states the trades were executed pursuant to a 10b5-1 trading plan adopted March 12, 2025 and amended June 13, 2025, and discloses vesting terms for the option: one-third vested on February 26, 2025 with annual vesting thereafter.
IonQ director and Chief Administrative Officer Paul T. Dacier sold 4,175 shares of IonQ common stock on 09/11/2025 at a weighted average price of $44.4016 per share, reducing his beneficial ownership to 114,454 shares. The filing states the sale was a "sell-to-cover" to satisfy statutory tax withholding obligations arising from the vesting of restricted stock units, and the reported sales occurred at prices ranging from $43.41 to $45.505. The Form 4 was signed by an attorney-in-fact on 09/12/2025.
IonQ insider sale related to tax withholding on vested RSUs. Chief Revenue Officer Rima Alameddine sold 19,976 shares of IonQ common stock on 09/11/2025 as a "sell-to-cover" to satisfy statutory tax withholding following RSU vesting. The weighted average price reported for the shares sold was $44.4016, with individual sale prices ranging from $43.41 to $45.505. After the transactions, the reporting person beneficially owned 532,616 shares, reported as direct ownership. The filing was signed by an attorney-in-fact on 09/12/2025. Explanatory footnotes state the sale was mandated by the issuer's equity plan and not a discretionary sale by the reporting person.
IonQ, Inc. director and President & CEO Niccolo de Masi reported the sale of 16,120 shares of IonQ common stock on 09/11/2025. The filing states these sales were executed as a sell-to-cover to satisfy statutory tax withholding obligations upon vesting of restricted stock units, not as discretionary open-market dispositions. The weighted-average price for the shares sold is reported as $44.4016, with individual trade prices ranging from $43.41 to $45.505. After the transaction, de Masi beneficially owns 1,181,186 shares, held directly.
IonQ, Inc. insider filing reports a proposed sale of 129,670 common shares through Morgan Stanley on 09/12/2025, with an aggregate market value of $6,100,973.50. The shares were originally acquired on 02/24/2021 from the issuer by exercise of stock options, paid in cash. The filing lists total outstanding shares of 296,837,796, and discloses that the same account sold 461,214 shares under 10b5-1 plans during the prior three months, generating gross proceeds of $19,044,783.58. The filer certifies there is no undisclosed material adverse information and references Rule 10b5-1 plan usage.